CML cells resistant to imatinib due to the BCR-ABL1T315I mutation exhibited increased expression of integrin β3 and integrin-linked kinase (ILK), a component of the focal adhesosome, as well as altered niche localization compared to BCR-ABL1WT cells. Here, ILK is linked to chronic myelogenous leukemia, BCR-ABL1 positive.